European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
M Baccarani, MW Deininger, G Rosti… - Blood, The Journal …, 2013 - ashpublications.org
Advances in chronic myeloid leukemia treatment, particularly regarding tyrosine kinase
inhibitors, mandate regular updating of concepts and management. A European …
inhibitors, mandate regular updating of concepts and management. A European …
The chronic myeloid leukemia stem cell: stemming the tide of persistence
TL Holyoake, D Vetrie - Blood, The Journal of the American …, 2017 - ashpublications.org
Chronic myeloid leukemia (CML) is caused by the acquisition of the tyrosine kinase BCR-
ABL1 in a hemopoietic stem cell, transforming it into a leukemic stem cell (LSC) that self …
ABL1 in a hemopoietic stem cell, transforming it into a leukemic stem cell (LSC) that self …
Chronic myeloid leukemia, version 2.2021, NCCN clinical practice guidelines in oncology
MW Deininger, NP Shah, JK Altman, E Berman… - Journal of the National …, 2020 - jnccn.org
Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome
(Ph) which results from a reciprocal translocation between chromosomes 9 and 22 [t (9; 22] …
(Ph) which results from a reciprocal translocation between chromosomes 9 and 22 [t (9; 22] …
Chronic myeloid leukemia, version 1.2019, NCCN clinical practice guidelines in oncology
JP Radich, M Deininger, CN Abboud, JK Altman… - Journal of the National …, 2018 - jnccn.org
Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome
(Ph), resulting from a reciprocal translocation between chromosomes 9 and 22 [t (9; 22] that …
(Ph), resulting from a reciprocal translocation between chromosomes 9 and 22 [t (9; 22] that …
Ponatinib in refractory Philadelphia chromosome–positive leukemias
JE Cortes, H Kantarjian, NP Shah… - … England Journal of …, 2012 - Mass Medical Soc
Background Resistance to tyrosine kinase inhibitors in patients with chronic myeloid
leukemia (CML) and Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph …
leukemia (CML) and Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph …
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective …
FX Mahon, D Réa, J Guilhot, F Guilhot, F Huguet… - The lancet …, 2010 - thelancet.com
Background Imatinib treatment significantly improves survival in patients with chronic
myeloid leukaemia (CML), but little is known about whether treatment can safely be …
myeloid leukaemia (CML), but little is known about whether treatment can safely be …
[HTML][HTML] Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia
H Kantarjian, NP Shah, A Hochhaus… - … England Journal of …, 2010 - Mass Medical Soc
Background Treatment with dasatinib, a highly potent BCR-ABL kinase inhibitor, has
resulted in high rates of complete cytogenetic response and progression-free survival …
resulted in high rates of complete cytogenetic response and progression-free survival …
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet
Purpose To review and update the European LeukemiaNet (ELN) recommendations for the
management of chronic myeloid leukemia with imatinib and second-generation tyrosine …
management of chronic myeloid leukemia with imatinib and second-generation tyrosine …
Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib
D Marin, A Bazeos, FX Mahon, L Eliasson… - Journal of clinical …, 2010 - ascopubs.org
Purpose There is a considerable variability in the level of molecular responses achieved
with imatinib therapy in patients with chronic myeloid leukemia (CML). These differences …
with imatinib therapy in patients with chronic myeloid leukemia (CML). These differences …
Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)
HM Kantarjian, NP Shah, JE Cortes… - Blood, The Journal …, 2012 - ashpublications.org
Dasatinib is a highly potent BCR-ABL inhibitor with established efficacy and safety in
imatinib-resistant/-intolerant patients with chronic myeloid leukemia (CML). In the phase 3 …
imatinib-resistant/-intolerant patients with chronic myeloid leukemia (CML). In the phase 3 …